A brand new biotech – Neurosterix – has been formed to take forward neuroscience programmes that originated at Switzerland’s Addex Therapeutics including a drug for schizophrenia.
Neurosterix has stepped out of the shadows with $63 million from a first-round financing led by life sciences investment group Perceptive Advisors that will be used for a portfolio of allosteric modulators for neurological disorders.
